Pharmaceutical

Otsuka and ShapeTX to develop gene therapies for eye di...

Otsuka Pharmaceutical has entered a partnership with ShapeTX for the development...

NICE recommends Lilly’s tirzepatide to treat T2D

The UK NICE has recommended Eli Lilly’s tirzepatide for the treatment of adult p...

EC expands indication approval for Merck’s Ebola vaccine

The European Commission granted expanded indication approval for Merck’s Ebola v...

Biocytogen and Myricx Bio partner for development of ADCs

Biocytogen and Myricx Bio have signed an antibody evaluation, option and licence...

Subcutaneous drugs grant a new lease on life to checkpo...

The PD-1/PD-L1 inhibitor landscape is at the precipice of change with the approv...

ALS advocates say criticism of new drugs misses bigger ...

Brian Wallach, ALS advocate: “We know that these treatments are not cures, but t...

How a supplement company became a haven for health misi...

“The idea that these supplements would be marketed in a way that people have a h...

STAT+: Why Novartis is changing the name of its researc...

Swiss drugmaker Novartis’ research and development hub has a new name — and a ne...

An uncommon thyroid diagnosis led to an unexpected, all...

“I think the worst thing you can do is try to put on a brave face and say, well,...

Opinion: Sanofi CEO Paul Hudson: The right way to bring...

“AI has the potential to improve and reinvent the way pharma operates,” writes P...

Opinion: How the drug price negotiation program could a...

Prescription drug plans and drug manufacturers might not be thrilled with price ...

Group behind ProMED fires three top moderators amid strike

The organization that runs the infectious diseases surveillance system ProMED te...

Back to school for biotech, Biogen’s potential pivot, &...

Are there still too many biotech companies? How do you know when you're in a bub...

Trump surgeon general admits Trump White House made mis...

The Trump administration made some serious missteps during the coronavirus pande...

Biotech execs vie for a share of obesity drug boom: ‘It...

“We’re really just at the beginning of what’s going to be a very long journey in...

STAT+: Amazon’s chief medical officers on where the com...

“If we're going to do it, let's make sure we're leveraging things that Amazon do...